View this on-demand webinar for an in-depth discussion on patient outcomes tracking through registries and how leveraging patient outcomes data collected from the first-generation of approved cell and gene therapies can inform the advancement of future cell and gene therapy products. Also included is a Q&A session between live webinar attendees and the following experts:…
HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes. During this on-demand webinar, you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal. You’ll…
As your therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity—and risk—increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain logistics partner. Keep these key considerations top of mind as you evaluate whether potential…
The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, you need an advanced approach to overcome barriers to on-time delivery. In our more than 30 years of experience managing the collection and delivery for time-sensitive cell therapies around the…
Orchestrating cell and gene therapy logistics is complex and susceptible to variability at each point of the supply chain. When shipments are life-critical, delays and oversights can be fatal. As operations scale from small populations in early-phase clinical trials to larger populations in late-stage trials and commercial launch, your supply chain complexity and risk increases.…
Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…
Human leukocyte antigens (HLAs), which are proteins found on the surface of most human cells, are fundamental to the success of matching potentially life-saving donors with patients in need of a blood stem cell transplant. Immune cells use HLAs to protect one’s own cells from invading microbes and viruses. A properly functioning immune system will…
When patients’ lives rely on a manufactured cell or gene therapy arriving exactly when and where it needs to, it is essential to ensure each step of the critical supply chain is managed as efficiently as possible. Cellular starting material collection is at the beginning of that supply chain, making cell collection processes vital to…
To identify a sufficient number of donors who meet study eligibility, health authority and medical suitability requirements, a large donor pool is required even for the most common HLA genotypes. Choose a partner whose registry size and diversity are built to scale with you. Discover how accessing the most diverse registry of potential donors in…